Physician profile
Norman D Jaffe
NPI 1386630549
$195,220.61
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $26K · 2021: $29K · 2022: $59K · 2023: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $1,827 · Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,525.00 |
| Travel and Lodging | $1,827.34 |
| Food and Beverage | $122.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $72,533.29 | 2019-2022 | |
| Lilly USA, LLC | $48,740.92 | 2020-2023 | Jardiance |
| Amarin Pharma, INC. | $24,372.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $17,978.95 | 2019 | |
| Amgen INC. | $11,554.06 | 2019-2021 | |
| Boston Scientific Corporation | $11,519.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $6,886.30 | 2019 | |
| Zoll Medical Corporation | $335.00 | 2020 | |
| Vifor (International) LTD. | $325.00 | 2020 | |
| Becton, Dickinson and Company | $320.00 | 2021 | |
| Medtronic Vascular, INC. | $137.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $137.10 | 2019 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.35 | 2019-2021 | |
| Gilead Sciences, INC. | $42.56 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $25.08 | 2019 | |
| Novo Nordisk INC | $20.15 | 2019 | |
| Abiomed | $17.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.19 | 2019 | |
| Pfizer INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.